Precision vs Power – The Next Generation of Immune Reset
For over a decade, cell therapy in cancer has embraced a simple philosophy: maximum firepower to eliminate malignant cells.
As these powerful tools enter autoimmune disease trials, however, a fascinating evolution is underway as companies begin releasing research on their pipelines at conferences.
Are the data breathing fire – or even too much of it?
From the early groundbreaking lupus studies to more precision targeting tools coming through preclinical development, researchers are discovering that finesse may well trump force when it comes to treating chronic inflammatory conditions.
This shift – from indiscriminate B cell destruction to more selective targeting of disease-driving cells – could redefine how we reset dysfunctional immune systems.
New data from the American College of Rheumatology (ACR) meeting held this week in Washington DC showcases this transformation while highlighting innovative approaches under the radar, which may finally thread the needle between efficacy and safety.
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
We’re at the point in time in the cancer conference calendar where we are rolling out AACR analyses and interviews while also highlighting relevant ASCO abstracts to watch out for.
Not in San Diego: We took a close look at the potential for targeting gamma delta (𝞬𝝳) T cells early last year in an extended mini-series looking at the landscape including some of the early companies leading the way in this niche.